we create universal target degraders to improve human and planetary health
problem
Expensive, complex, and limited by safety and scalability, today’s antibody-based therapies face major limitations in safety, scalability, and reach
solution
Tomorrow’s antibody-based therapy starts with novel universal target degraders, designed for greater safety, manufacturability, and affordability
antibodies are therapeutic biomolecules known for their specific targeting of almost any antigens
enzymes can break down proteins into smaller components like peptides, polypeptides or single amino acids
we combine antibody and enzyme in one molecule called abzyme
abzymes are omni-functional molecules that combine the binding specificity of antibodies (ab-) with the enzyme-mediated target elimination (-zymes) in one
millions of molecules serve as potential targets for precise and guided degradation to improve people and planetary health
we eliminate any target of interest based on specific binding and targeted degradation
abzymes are universal target degraders accessible to the majority of the world’s population at an affordable price
abzign 